Cosmos Health Inc. (NASDAQ:COSM – Get Free Report) CEO Grigorios Siokas acquired 113,185 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average cost of $0.50 per share, with a total value of $56,592.50. Following the completion of the purchase, the chief executive officer owned 7,244,979 shares of the company’s stock, valued at $3,622,489.50. This trade represents a 1.59% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Grigorios Siokas also recently made the following trade(s):
- On Thursday, January 8th, Grigorios Siokas bought 156,190 shares of Cosmos Health stock. The stock was bought at an average cost of $0.52 per share, for a total transaction of $81,218.80.
- On Wednesday, January 7th, Grigorios Siokas bought 124,880 shares of Cosmos Health stock. The shares were bought at an average price of $0.52 per share, for a total transaction of $64,937.60.
- On Tuesday, January 6th, Grigorios Siokas bought 133,953 shares of Cosmos Health stock. The shares were bought at an average price of $0.54 per share, with a total value of $72,334.62.
- On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The stock was bought at an average cost of $0.49 per share, with a total value of $43,273.86.
- On Monday, December 15th, Grigorios Siokas purchased 168,472 shares of Cosmos Health stock. The stock was purchased at an average price of $0.42 per share, for a total transaction of $70,758.24.
- On Friday, November 28th, Grigorios Siokas acquired 76,360 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.64 per share, for a total transaction of $48,870.40.
- On Tuesday, November 25th, Grigorios Siokas bought 55,732 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.63 per share, with a total value of $35,111.16.
- On Friday, November 21st, Grigorios Siokas bought 56,080 shares of Cosmos Health stock. The stock was purchased at an average price of $0.68 per share, for a total transaction of $38,134.40.
- On Thursday, November 20th, Grigorios Siokas purchased 51,315 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.62 per share, for a total transaction of $31,815.30.
- On Wednesday, November 19th, Grigorios Siokas acquired 61,614 shares of Cosmos Health stock. The stock was purchased at an average price of $0.65 per share, with a total value of $40,049.10.
Cosmos Health Trading Up 1.9%
Shares of Cosmos Health stock traded up $0.01 during trading hours on Tuesday, hitting $0.51. The company’s stock had a trading volume of 610,842 shares, compared to its average volume of 646,326. The stock has a 50 day moving average of $0.57 and a 200 day moving average of $0.73. Cosmos Health Inc. has a 12 month low of $0.28 and a 12 month high of $1.32. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84. The company has a market capitalization of $19.20 million, a PE ratio of -0.68 and a beta of 5.37.
Institutional Investors Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC increased its stake in shares of Cosmos Health Inc. (NASDAQ:COSM – Free Report) by 133.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,507 shares of the company’s stock after purchasing an additional 128,776 shares during the quarter. Citadel Advisors LLC owned approximately 0.65% of Cosmos Health worth $250,000 at the end of the most recent reporting period. 12.61% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities research analysts have recently commented on COSM shares. Wall Street Zen raised Cosmos Health to a “hold” rating in a report on Saturday, September 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cosmos Health in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.
View Our Latest Report on Cosmos Health
Cosmos Health Company Profile
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Read More
- Five stocks we like better than Cosmos Health
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- This stock gets a 94 out of 100
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
